

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/624,946
Filing Date	July 21, 2003
First Named Inventor	Jeffrey R. Raymond
Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket No.	480117.407C1

ENCLOSURES (check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1449 (2 Sheets) Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application		Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):			
Remarks	Remarks					
	CICNIATUE	DE OF ADDITIONAL ATTORNEY	OD ACENT			
Individual Name	Carol J. Roth Reg. No. 32,		Customer Number 00500			
Signature	Signature Carol J Roth					
Date October 20, 2003						
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope						
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.						
Typed or printed n	ame Law	rence Teague				
Signature	X	Evere /earno	Date: October 20, 2003			
This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.16. This collection is estimated to take 12 minutes to complete, including gathering,						

This collection of information is fequired by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 20, 2003

Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Jeffrey R. Raymond et al.

Application No.

10/624,946

Filed

July 21, 2003

For

3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES

RELATED THERETO

Docket No.

: 480117.407C1

Date

: October 17, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/845,775, filed April 30, 2001, now issued as U.S. Patent 6,635,629. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request.

Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Jeffrey R. Raymond

Carol of Rotm

Seed Intellectual Property Law Group PLLC

Carol J. Roth

Registration No. 32,783

CJR:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 (2 Sheets)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\426117

FORM PTO 1449 (REV.7-80) INFORMATION DISCLOSURE STATEMENT

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

ATTY. DOCKET NO. 480117.407C1 APPLICATION NO. 10/624,946

APPLICANTS

Jeffrey R. Raymond et al.

FILING DATE

GROUP ART UNIT

July 21, 2003

Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	AA	5,637,691	06/10/97	Frye et al.	540	106	
	AB	5,721,226	02/24/98	Frye et al.	514	169	
	AC	5,733,899	03/31/98	Frye et al.	514	169	
	AD	5,817,632	10/06/98	Hsia	514	21	
	AE	5,847,172	12/08/98	Zasloff et al.	552	521	
	AF	5,856,535	01/05/99	Zasloff et al.	552	521	
	AG	5,874,597	02/23/99	Jones	552	521	
•	AH	6,046,185	04/04/00	Burgoyne et al.	514	178	
	ΑI	6,060,465	05/09/00	Miljkovic et al.	514	169	
	AJ						

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	TRANSL	LATION	
 <u> </u>	NUMBER	DATE	COUNTRY	YES	NO	
AK	WO 91/10743	07/25/91	WIPO			
AL	WO 94/14451	07/07/94	WIPO			
AM	WO 94/20520	09/15/94	WIPO			
AN	WO 96/22791	08/01/96	WIPO			
AO	WO 96/36230	11/21/96	WIPO			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Cram and Allinger, "Mold Metabolites. VIII. Contribution to the Elucidation of the Structure of
	Helvolic Acid," Journal of the American Chemical Society 78:5275-5284, October 20, 1956.
AQ	Foussard-Blanpin, "Pharmacological Study of 3α-Aminopregnane," Ann. Pharm. FR.
Ì	27(3):191-200, 1969. (Abstract Only, STN Accession No. 71:79454)
AR	McGowan et al., "The Production of a Reactive Oxygen Intermediate during the Induction of Apoptosis by Cytotoxic Insult," <i>Experimental Cell Research 238</i> (1):248-256,
	January 10, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OCT 2 3 2003

	152.	
FORM PTO-14	49(5)	
(REV.7-80)	G TRADE	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 480117.407C1

APPLICATION NO. 10/624,946

APPLICANTS

(Use several sheets if necessary)

Jeffrey R. Raymond et al.

FILING DATE

GROUP ART UNIT

July 21, 2003

Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
***	ВА						
	вв						
	вс						
	BD		····				
***	ВЕ						
	BF						
	BG						
•	вн						
•	ві						
	ВЈ						

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	TRANS	LATION	
	NUMBER	DATE	COUNTRY	YES	NO	
вк	WO 98/02450	01/22/98	WIPO			
BL	WO 98/27106	06/25/98	WIPO			
ВМ	WO 99/44616	09/10/99	WIPO			
BN						
во						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ВР	Mendenhall et al., "Anabolic Steriod Effects on Immune Function: Differences Between Analogs," <i>J. Steriod Biochem. Mol. Biol</i> 37(1):71-76, 1990. (Abstract Only, STN Accession No. 114:17714)
BQ	Spyriounis et al., "Novel N-Substituted 3-Aminosteroids Which Exhibit Anti-Inflammatory Properties and Influence Free Radical Processes," Eur. J. Med. Chem. 28(6):521-525, 1993.
BR	

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).